Market Closed -
Nasdaq
04:30:00 2024-06-05 pm EDT
|
5-day change
|
1st Jan Change
|
8.8
USD
|
+3.53%
|
|
-3.40%
|
-17.94%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
239
|
112.2
|
56.34
|
31.62
|
26.04
|
-
|
-
|
Enterprise Value (EV)
1 |
239
|
112.2
|
56.34
|
31.62
|
26.04
|
26.04
|
26.04
|
P/E ratio
|
-
|
-3.55
x
|
-1.19
x
|
-0.8
x
|
-0.82
x
|
-0.92
x
|
-1.43
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
70.8
x
|
26
x
|
37.8
x
|
40.3
x
|
25.2
x
|
32.6
x
|
26
x
|
EV / Revenue
|
70.8
x
|
26
x
|
37.8
x
|
40.3
x
|
25.2
x
|
32.6
x
|
26
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,438
|
2,471
|
2,817
|
2,948
|
2,960
|
-
|
-
|
Reference price
2 |
98.00
|
45.40
|
20.00
|
10.72
|
8.800
|
8.800
|
8.800
|
Announcement Date
|
3/11/21
|
3/10/22
|
3/9/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3.375
|
4.315
|
1.49
|
0.785
|
1.033
|
0.8
|
1
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-17.54
|
-31.37
|
-44.95
|
-41.71
|
-38.64
|
-48
|
-57
|
Operating Margin
|
-519.76%
|
-726.91%
|
-3,016.58%
|
-5,313.89%
|
-3,740.49%
|
-6,000.21%
|
-5,700%
|
Earnings before Tax (EBT)
1 |
-
|
-31.33
|
-44.17
|
-39.48
|
-37.01
|
-46.02
|
-56
|
Net income
1 |
-
|
-31.33
|
-44.17
|
-39.48
|
-37.12
|
-46.91
|
-56
|
Net margin
|
-
|
-726.14%
|
-2,964.43%
|
-5,029.17%
|
-3,593.8%
|
-5,864.25%
|
-5,600%
|
EPS
2 |
-
|
-12.80
|
-16.80
|
-13.43
|
-10.78
|
-9.593
|
-6.160
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/21
|
3/10/22
|
3/9/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.556
|
0.746
|
0.191
|
0.382
|
0.171
|
0.203
|
0.106
|
0.179
|
0.297
|
0.569
|
0.1638
|
0.1638
|
0.1365
|
0.2
|
0.2
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-8.08
|
-9.912
|
-11.8
|
-11.32
|
-11.92
|
-12.14
|
-9.545
|
-10.39
|
-9.636
|
-8.779
|
-9.492
|
-10.05
|
-10.32
|
-10.95
|
-11.24
|
Operating Margin
|
-1,453.24%
|
-1,328.69%
|
-6,175.39%
|
-2,964.66%
|
-6,967.84%
|
-5,981.77%
|
-9,004.72%
|
-5,804.47%
|
-3,244.44%
|
-1,542.88%
|
-5,796.64%
|
-6,136.03%
|
-7,560.81%
|
-5,473.5%
|
-5,622.5%
|
Earnings before Tax (EBT)
1 |
-8.073
|
-9.904
|
-11.74
|
-11.12
|
-11.4
|
-11.49
|
-8.966
|
-9.862
|
-9.164
|
-8.388
|
-9.083
|
-9.716
|
-9.819
|
-10.68
|
-10.84
|
Net income
1 |
-8.073
|
-9.904
|
-11.74
|
-11.12
|
-11.4
|
-11.49
|
-8.966
|
-9.862
|
-9.164
|
-8.388
|
-9.083
|
-9.683
|
-9.97
|
-10.68
|
-10.84
|
Net margin
|
-1,451.98%
|
-1,327.61%
|
-6,147.12%
|
-2,912.3%
|
-6,666.67%
|
-5,658.62%
|
-8,458.49%
|
-5,509.5%
|
-3,085.52%
|
-1,474.17%
|
-5,546.87%
|
-5,913.13%
|
-7,304.03%
|
-5,341.5%
|
-5,419.5%
|
EPS
2 |
-3.400
|
-4.000
|
-4.600
|
-4.200
|
-4.000
|
-4.000
|
-3.000
|
-3.400
|
-3.110
|
-2.830
|
-3.032
|
-2.658
|
-2.525
|
-2.420
|
-2.190
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/5/22
|
8/9/22
|
11/3/22
|
3/9/23
|
5/4/23
|
8/10/23
|
11/9/23
|
3/7/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/21
|
3/10/22
|
3/9/23
|
3/7/24
|
-
|
-
|
-
|
Average target price
27.67
USD Spread / Average Target +214.39% Consensus |
1st Jan change
|
Capi.
|
---|
| -17.94% | 26.04M | | +55.70% | 59.34B | | +42.72% | 40.24B | | -5.39% | 39.88B | | -5.56% | 28.55B | | +16.46% | 27.26B | | -20.56% | 19.23B | | +33.03% | 12.61B | | +2.72% | 12.49B | | +25.85% | 12.28B |
Other Biotechnology & Medical Research
|